XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense
The following table summarizes the stock-based compensation expense recognized under all of the Company’s stock plans for the three and nine months ended September 30, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of operations (in thousands):

Three Months Ended
September 30,		Six Months Ended
September 30,
2022202120222021
Stock options$947 $602 $2,868 $1,794 
Restricted stock2,555 818 7,609 2,528 
Total stock-based compensation expense$3,502 $1,420 $10,477 $4,322 
Schedule of Stock Option Transactions Under Stock Option Plans
The Company’s outstanding stock options consisted of the following:
Shares
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
(in millions)
Options outstanding at January 1, 2022813,965 $22.74 3.20$41.6 
Options granted
87,488 51.21 — — 
Options exercised
(41,603)17.81 — 1.0 
Options outstanding at September 30, 2022859,850 $25.90 2.44$16.5 
Options exercisable at September 30, 2022639,622 $12.07 1.56$15.5 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
During the nine months ended September 30, 2022, the Company granted 87,488 stock options to certain ApolloMed employees and Board members. The options granted during the nine months ended September 30, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows:
September 30, 2022
Expected term
1.50 years - 2.25 years
Expected volatility
71.47% - 82.05%
Risk-free interest rate
1.02% - 2.47%
Market value of options
$17.47 - $23.42
Schedule of Outstanding Warrants
The Company’s outstanding warrants consisted of the following:
Shares
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
(in millions)
Warrants outstanding at January 1, 20221,001,740 10.49 0.9463.1 
Warrants granted— — — — 
Warrants exercised(281,742)10.49 — 10.1 
Warrants expired/forfeited— — — — 
Warrants outstanding at September 30, 2022719,998 $10.49 0.19$20.5 

Exercise Price Per Share
Warrants
Outstanding
Weighted
Average
Remaining
Contractual Life
Warrants
Exercisable
Weighted
Average
Exercise Price
Per Share
$10.00 370,2800.19370,280 $10.00 
11.00 349,7180.19349,718 $11.00 
$ 10.00 – 11.00
719,998 0.19719,998 $10.49